0001209191-18-058021.txt : 20181109 0001209191-18-058021.hdr.sgml : 20181109 20181109183903 ACCESSION NUMBER: 0001209191-18-058021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181107 FILED AS OF DATE: 20181109 DATE AS OF CHANGE: 20181109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schall Thomas J. CENTRAL INDEX KEY: 0001423084 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 181174383 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-07 0 0001340652 ChemoCentryx, Inc. CCXI 0001423084 Schall Thomas J. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 1 1 0 0 President and CEO Common Stock 2018-11-07 4 M 0 7211 6.00 A 2192205 D Common Stock 2018-11-07 4 S 0 7211 12.0031 D 2184994 D Stock Option (right to buy) 6.00 2018-11-07 4 M 0 7211 D 2009-07-29 2019-07-29 Common Stock 7211 216932 D Shares sold are associated with stock options that will expire in July 2019. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $12.00 to $12.03 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. As of November 7, 2018, and prior to this transaction, the exercised options were fully vested. Not applicable. /s/ Susan M. Kanaya, as Attorney-in-Fact 2018-11-09